open access

Vol 14, No 3 (2009)
Untitled
Published online: 2009-05-01
Submitted: 2009-05-29
Get Citation

Intensity modulated radiotherapy (IMRT) the white, black and grey: a clinical perspective

Joseph BINDHU, Sanjay SUPE, Yeshwanth PAWAR
DOI: 10.1016/S1507-1367(10)60101-0
·
Rep Pract Oncol Radiother 2009;14(3):95-103.

open access

Vol 14, No 3 (2009)
Untitled
Published online: 2009-05-01
Submitted: 2009-05-29

Abstract

The radiotherapy community has in the past few decades witnessed dramatic shift in the treatment modalities from conventional 2-D radiotherapy to the now widely practiced 3-DCRT, IMRT and evolving IGRT. IMRT has generated so much interest because of its unique dosimetric modulation to concentrate doses to the targets of interests while also being able to relatively spare neighboring normal tissue. However IMRT is not the all in one solution for radiotherapeutic management of solid malignancies. The current enthusiasm in IMRT most be tempered with an understanding of the complexities of IMRT planning, treatment delivery, quality assurance, monitoring and clinical limitations. The widespread implementation of this technological innovation may have been a bit premature considering that clinical information regarding the same is still being generated. This article tries to give an overview of the potential advantages/disadvantages of IMRT in the clinical set up and the few controversies (Grey Zone) that are still being resolved. There is evidence to indicate that indiscriminately used IMRT may even harm the patient or have an inferior therapeutic index to 3DCRT. This and other pertinent issues will be covered by the authors in this short review of IMRT in clinical practice.

Abstract

The radiotherapy community has in the past few decades witnessed dramatic shift in the treatment modalities from conventional 2-D radiotherapy to the now widely practiced 3-DCRT, IMRT and evolving IGRT. IMRT has generated so much interest because of its unique dosimetric modulation to concentrate doses to the targets of interests while also being able to relatively spare neighboring normal tissue. However IMRT is not the all in one solution for radiotherapeutic management of solid malignancies. The current enthusiasm in IMRT most be tempered with an understanding of the complexities of IMRT planning, treatment delivery, quality assurance, monitoring and clinical limitations. The widespread implementation of this technological innovation may have been a bit premature considering that clinical information regarding the same is still being generated. This article tries to give an overview of the potential advantages/disadvantages of IMRT in the clinical set up and the few controversies (Grey Zone) that are still being resolved. There is evidence to indicate that indiscriminately used IMRT may even harm the patient or have an inferior therapeutic index to 3DCRT. This and other pertinent issues will be covered by the authors in this short review of IMRT in clinical practice.

Get Citation

Keywords

intensity modulated radiotherapy; conformal radiotherapy; dose optimization; advances in radiotherapy

About this article
Title

Intensity modulated radiotherapy (IMRT) the white, black and grey: a clinical perspective

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 14, No 3 (2009)

Pages

95-103

Published online

2009-05-01

DOI

10.1016/S1507-1367(10)60101-0

Bibliographic record

Rep Pract Oncol Radiother 2009;14(3):95-103.

Keywords

intensity modulated radiotherapy
conformal radiotherapy
dose optimization
advances in radiotherapy

Authors

Joseph BINDHU
Sanjay SUPE
Yeshwanth PAWAR

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl